Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COPD-OMA
NCT07059091Phase 2Recruiting
- Sponsor
- Johns Hopkins University
- Start
- Feb 2026
- Primary completion
- Jan 2031
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of omalizumab in chronic obstructive pulmonary disease (COPD), allergy, sponsored by Johns Hopkins University. Started Feb 2026; status: recruiting.
02
Drugs
omalizumab
03
Conditions
chronic obstructive pulmonary disease (COPD)allergy
Beyond the preview
Go deeper on NCT07059091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07059091.